Literature DB >> 26912805

Mechanistic Study of Inhibitory Effects of Atorvastatin and Docetaxel in Combination on Prostate Cancer.

Xuan Chen1, Yue Liu2, Jian Wu3, Huarong Huang4, Zhiyun Du4, Kun Zhang4, Daiying Zhou5, Kaylyn Hung2, Susan Goodin6, Xi Zheng7.   

Abstract

AIM: To investigate the effects and mechanisms of docetaxel and atorvastatin administered individually or in combination on prostate cancer cells.
MATERIALS AND METHODS: Cell growth and apoptosis were determined by the trypan blue exclusion assay and morphological assessment of cells was performed with propidium iodide. NF-κB activity was determined by luciferase reporter gene assay and the western blot assay was used to determine the levels of Bcl-2, phospho-Akt, VEGF, and phospho-Erk1/2.
RESULTS: Results showed that following pre-treatment with cholesterol, resistance of PC-3 prostate cancer cells to docetaxel was increased. The combination of docetaxel with atorvastatin potently inhibited growth and induced apoptosis in PC-3 cells. Mechanistic studies indicated that induction of apoptosis in PC-3 cells was associated with significant decreases in the levels of Bcl-2, VEGF, phosphor-Akt, and phosphor-Erk1/2.
CONCLUSION: Treatment with cholesterol decreased the sensitivity of prostate cancer cells to docetaxel. Docetaxel in combination with cholesterol-lowering drugs such as atorvastatin may be an effective strategy for inhibiting the growth of prostate cancer. Copyright
© 2016, International Institute of Anticancer Research (Dr. John G. Delinasios), All rights reserved.

Entities:  

Keywords:  Combination treatment; atorvastatin; docetaxel; prostate cancer

Mesh:

Substances:

Year:  2016        PMID: 26912805      PMCID: PMC5203772     

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  46 in total

1.  Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer.

Authors:  T M Beer; W C Pierce; B A Lowe; W D Henner
Journal:  Ann Oncol       Date:  2001-09       Impact factor: 32.976

2.  The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Authors:  Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Journal:  Nature       Date:  2002-11-07       Impact factor: 49.962

3.  A Western-type diet accelerates tumor progression in an autochthonous mouse model of prostate cancer.

Authors:  Gemma Llaverias; Christiane Danilo; Yu Wang; Agnes K Witkiewicz; Kristin Daumer; Michael P Lisanti; Philippe G Frank
Journal:  Am J Pathol       Date:  2010-11-18       Impact factor: 4.307

4.  HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.

Authors:  Takayuki Ikezoe; Yasuko Hisatake; Tamotsu Takeuchi; Yuji Ohtsuki; Yang Yang; Jonathan W Said; Hirokuni Taguchi; H Phillip Koeffler
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

Review 5.  Key signalling nodes in mammary gland development and cancer. The Snail1-Twist1 conspiracy in malignant breast cancer progression.

Authors:  Ellen Foubert; Bram De Craene; Geert Berx
Journal:  Breast Cancer Res       Date:  2010-06-25       Impact factor: 6.466

Review 6.  Cholesterol accumulation in prostate cancer: a classic observation from a modern perspective.

Authors:  James Robert Krycer; Andrew John Brown
Journal:  Biochim Biophys Acta       Date:  2013-01-26

7.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Prostate cancer. NCCN clinical practice guidelines in oncology.

Authors: 
Journal:  J Natl Compr Canc Netw       Date:  2004-05       Impact factor: 11.908

9.  Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.

Authors:  K L Tedesco; A D Thor; D H Johnson; Y Shyr; K A Blum; L J Goldstein; W J Gradishar; B P Nicholson; D E Merkel; D Murrey; S Edgerton; G W Sledge
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

10.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

View more
  12 in total

1.  Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro.

Authors:  Hannah M Jones; Ziwei Fang; Wenchuan Sun; Leslie H Clark; Jessica E Stine; Arthur-Quan Tran; Stephanie A Sullivan; Timothy P Gilliam; Chunxiao Zhou; Victoria L Bae-Jump
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

2.  Atorvastatin and Caffeine in Combination Regulates Apoptosis, Migration, Invasion and Tumorspheres of Prostate Cancer Cells.

Authors:  Zhenshi Wang; Lanyue Zhang; Zheng Wan; Yan He; Huarong Huang; Hongping Xiang; Xiaofeng Wu; Kun Zhang; Yang Liu; Susan Goodin; Zhiyun Du; Xi Zheng
Journal:  Pathol Oncol Res       Date:  2018-05-24       Impact factor: 3.201

3.  Synthesis of Psoralidin derivatives and their anticancer activity: First synthesis of Lespeflorin I1.

Authors:  Pallab Pahari; Ujwal Pratim Saikia; Trinath Prasad Das; Chendil Damodaran; Jurgen Rohr
Journal:  Tetrahedron       Date:  2016-06-09       Impact factor: 2.457

4.  The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.

Authors:  Lin Yu; Xiaofeng Wu; Min Chen; Huarong Huang; Yan He; Huaqian Wang; Dongli Li; Zhiyun Du; Kun Zhang; Susan Goodin; Xi Zheng
Journal:  Int J Med Sci       Date:  2017-04-07       Impact factor: 3.738

5.  Identification of simvastatin-regulated targets associated with JNK activation in DU145 human prostate cancer cell death signaling.

Authors:  Eun Joo Jung; Ky Hyun Chung; Choong Won Kim
Journal:  BMB Rep       Date:  2017-09       Impact factor: 4.778

6.  Celecoxib combined with salirasib strongly inhibits pancreatic cancer cells in 2D and 3D cultures.

Authors:  Dongli Li; Yuran Ma; Wenfeng Liu; Xiang Ren; Min Chen; Xuetao Xu; Zhaojun Sheng; Kun Zhang; Renping Zhou; Susan Goodin; Xi Zheng
Journal:  Int J Med Sci       Date:  2020-07-09       Impact factor: 3.738

7.  Toll-Like Receptor-4 Disruption Suppresses Adipose Tissue Remodeling and Increases Survival in Cancer Cachexia Syndrome.

Authors:  Felipe Henriques; Magno A Lopes; Felipe O Franco; Pamela Knobl; Kaltinaitis B Santos; Luana L Bueno; Victor A Correa; Alexander H Bedard; Adilson Guilherme; Alexander Birbrair; Sidney B Peres; Stephen R Farmer; Miguel L Batista
Journal:  Sci Rep       Date:  2018-12-21       Impact factor: 4.379

8.  Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.

Authors:  Federica Iannelli; Maria Serena Roca; Rita Lombardi; Chiara Ciardiello; Laura Grumetti; Simona De Rienzo; Tania Moccia; Carlo Vitagliano; Angela Sorice; Susan Costantini; Maria Rita Milone; Biagio Pucci; Alessandra Leone; Elena Di Gennaro; Rita Mancini; Gennaro Ciliberto; Francesca Bruzzese; Alfredo Budillon
Journal:  J Exp Clin Cancer Res       Date:  2020-10-08

9.  Antiangiogenic and Proapoptotic Activities of Atorvastatin and Ganoderma lucidum in Tumor Mouse Model via VEGF and Caspase-3 Pathways.

Authors:  Iman Hesham El-Khashab
Journal:  Asian Pac J Cancer Prev       Date:  2021-04-01

10.  Atorvastatin Enhances Effects of Radiotherapy on Prostate Cancer Cells and Xenograft Tumor Mice Through Triggering Interaction Between Bcl-2 and MSH2.

Authors:  Zhenhua He; Jingmin Yuan; Fuhui Shen; Fangang Zeng; Ping Qi; Zhiping Wang; Zhenxing Zhai
Journal:  Med Sci Monit       Date:  2020-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.